TTK Healthcare Limited (TTKHLTCARE.NS)
INR 1456.8
(-2.39%)
INR 1456.8
(-2.39%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.99 Billion INR | -7.87% |
| 2022 | 2.16 Billion INR | -5.33% |
| 2021 | 2.28 Billion INR | 14.67% |
| 2020 | 1.99 Billion INR | 9.56% |
| 2019 | 1.82 Billion INR | 10.85% |
| 2018 | 1.64 Billion INR | -5.7% |
| 2017 | 1.74 Billion INR | 28.49% |
| 2016 | 1.35 Billion INR | -18.43% |
| 2015 | 1.66 Billion INR | 5.98% |
| 2014 | 1.56 Billion INR | 17.98% |
| 2013 | 1.33 Billion INR | 19.7% |
| 2012 | 1.11 Billion INR | -11.58% |
| 2011 | 1.25 Billion INR | 6.78% |
| 2010 | 1.17 Billion INR | 31.16% |
| 2009 | 897.34 Million INR | 18.0% |
| 2008 | 760.49 Million INR | 23.09% |
| 2007 | 617.83 Million INR | 11.92% |
| 2006 | 552.02 Million INR | 0.17% |
| 2005 | 551.09 Million INR | -3.14% |
| 2004 | 568.95 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 2.27 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 2.09 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 1.99 Billion INR | -7.87% |
| 2023 Q4 | 1.99 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 3.09 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 2.16 Billion INR | -5.33% |
| 2022 Q4 | 2.16 Billion INR | 0.0% |
| 2021 FY | 2.28 Billion INR | 14.67% |
| 2021 Q4 | 2.28 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 2.19 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 1.92 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 1.99 Billion INR | 9.56% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 1.99 Billion INR | 0.0% |
| 2019 Q4 | 1.82 Billion INR | 0.0% |
| 2019 FY | 1.82 Billion INR | 10.85% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 1.88 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q2 | 1.77 Billion INR | 0.0% |
| 2018 FY | 1.64 Billion INR | -5.7% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 1.64 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q4 | 1.74 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 1.51 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 1.74 Billion INR | 28.49% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 1.35 Billion INR | -18.43% |
| 2016 Q4 | 1.35 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 155767.21 Billion INR | 0.0% |
| 2015 FY | 1.66 Billion INR | 5.98% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 1.66 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 1.66 Billion INR | 0.0% |
| 2014 Q2 | 1.6 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 1.56 Billion INR | 17.98% |
| 2014 Q4 | 1.56 Billion INR | 0.0% |
| 2013 Q2 | 1.19 Billion INR | 0.0% |
| 2013 FY | 1.33 Billion INR | 19.7% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 1.33 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 FY | 1.11 Billion INR | -11.58% |
| 2012 Q4 | 1.11 Billion INR | 0.0% |
| 2011 FY | 1.25 Billion INR | 6.78% |
| 2011 Q4 | 1.25 Billion INR | 0.0% |
| 2010 FY | 1.17 Billion INR | 31.16% |
| 2009 FY | 897.34 Million INR | 18.0% |
| 2008 FY | 760.49 Million INR | 23.09% |
| 2007 FY | 617.83 Million INR | 11.92% |
| 2006 FY | 552.02 Million INR | 0.17% |
| 2005 FY | 551.09 Million INR | -3.14% |
| 2004 FY | 568.95 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Abbott India Limited | 14.94 Billion INR | 86.64% |
| Cipla Limited | 59.15 Billion INR | 96.625% |
| Gland Pharma Limited | 19.37 Billion INR | 89.694% |
| GlaxoSmithKline Pharmaceuticals Limited | 17.96 Billion INR | 88.883% |
| Kopran Limited | 2.52 Billion INR | 20.764% |
| Marksans Pharma Limited | 5.95 Billion INR | 66.444% |
| NGL Fine-Chem Limited | 929.03 Million INR | -114.927% |
| Pfizer Limited | 6.33 Billion INR | 68.468% |
| Sanofi India Limited | 6.99 Billion INR | 71.459% |
| SMS Pharmaceuticals Limited | 4.97 Billion INR | 59.885% |